NCT05246345 Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
| NCT ID | NCT05246345 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Clermont-Ferrand |
| Condition | Chronic Lymphocytic Leukemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2022-03-07 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2022-03-07 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to collect medical informations and samples from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax treatment, in order to evaluate the frequency of resistance mechanisms.
Eligibility Criteria
Inclusion Criteria: * Age greater than or equal to 18 years old; * chronic lymphocytic leukemia diagnosis according to iwCLL criteria; * refractory and/or relapsed disease during or after venetoclax treatment; * tumor samples available. * Relapse might be progressive chronic lymphocytic leukemia or transformation into Richter syndrome. * Patients must be able to express their opposition to be enrolled in this study, if need be. * Patients must be affiliated at the French Social Security system Exclusion Criteria: Patients of their legal guardians refusing to participate \-
Contact & Investigator
Romain GUIEZE
PRINCIPAL INVESTIGATOR
University Hospital, Clermont-Ferrand
Frequently Asked Questions
Who can join the NCT05246345 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Lymphocytic Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05246345 currently recruiting?
Yes, NCT05246345 is actively recruiting participants. Contact the research team at promo_interne_drci@chu-clermontferrand.fr for enrollment information.
Where is the NCT05246345 trial being conducted?
This trial is being conducted at Amiens, France, Besançon, France, Bobigny, France, Clermont-Ferrand, France and 10 additional locations.
Who is sponsoring the NCT05246345 clinical trial?
NCT05246345 is sponsored by University Hospital, Clermont-Ferrand. The principal investigator is Romain GUIEZE at University Hospital, Clermont-Ferrand. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.